DKK1 oncogene as therapeutic target for cancer and a diagnosing marker
AssigneeOncotherapy Science, Inc.
InventorsYusuke Nakamura, Yataro Daigo, Shuichi Nakatsuru
Life of this patent
Estimating the term…
Abstract
Described herein are antibodies and antibody fragments capable of treating or preventing cancers associated with the over-expression and/or up-regulation of DKK1. Also disclosed are methods of treating or preventing cancer using the antibody and methods and kits utilized to diagnosing cancer. The herein described products and methods find utility in the context of a variety of cancers, such as pancreatic cancer, gastric cancer, liver cancer, prostate cancer, breast cancer, cervical cancer, bile duct cancer, lung cancer and esophageal cancer.
Claims6
A method for identifying a subject in need of therapy for a cancer, the method comprising:
- (a) contacting an antibody against DKK1 protein with a blood or blood derived sample from a subject suspected of suffering from a cancer selected from the group consisting of pancreatic cancer, gastric cancer, prostate cancer, bile duct cancer and cervical cancer to determine a blood concentration of a DKK1 protein in the blood or blood derived sample;
- (b) obtaining a biological sample comprising pancreatic, gastric, prostate, bile duct, or cervical tissue from the subject by surgery or biopsy if the blood concentration of DKK1 protein in the blood or blood derived sample from the subject is greater than a normal control level in a blood or a blood derived sample;
- and
- (c) determining the level of DKK1 protein in the biological sample, and
- (d) identifying the subject in need of therapy for a cancer if the level of DKK1 protein in the biological sample is greater than the level in a control biological sample comprising pancreatic, gastric, prostate, bile duct, or cervical tissue.
A method of diagnosing a cancer in pancreatic, gastric, prostate, bile duct, or cervical tissue in a subject, the method comprising:
- (a) obtaining a biological sample from a subject selected from the group consisting of pancreatic, gastric, prostate, bile duct, and cervical tissue;
- (b) contacting an antibody against DKK1 protein with the biological sample collected in step (a) to determine a level of DKK1 protein in the biological sample;
- (c) providing a diagnosis that the subject suffers from pancreatic cancer, gastric cancer, prostate cancer, bile duct cancer, or cervical cancer if the level of DKK1 protein in the biological sample from the subject is greater than a normal control level.
Dependencies are inferred from the claim text.